Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX).
暂无分享,去创建一个
D. Shin | D. Cunningham | I. Láng | V. Lorusso | D. Jonker | M. Saunders | D. Waterkamp | J. Ocvirk | S. Osborne | N. Andre